Phillip Wong
Scientist
Ludwig Center at MSKÂ
Ludwig Institute for Cancer Research
United States of America
Biography
As head of the Immune Monitoring Facility in MSKCC's Ludwig Center for Cancer Immunotherapy, I am dedicated to the development and provision of world-class, cutting-edge immune monitoring technology to support a wide variety of ongoing cancer immunotherapy clinical trials. We provide clinical sample banking services as well as robust, standardized serological and cellular assays to identify immune correlates and biomarkers of clinical outcomes. I received my PhD in immunology from the University of Washington and was a postdoctoral research fellow in the Immunology Program at MSKCC. Before joining the Immune Monitoring Facility I spent more than eight years in the pharmaceutical industry at Wyeth and Roche, where I was a senior scientist supporting therapeutic programs in vaccines and inflammatory diseases with an emphasis on the clinical translation of laboratory assays.
Research Interest
Immunotherapy, cancer treatment, cancer biology, serological and cellular assays
Publications
-
Wong, Phillip, and Eric G. Pamer. "CD8 T cell responses to infectious pathogens." Annual review of immunology 21.1 (2003): 29-70.
-
Rizvi, Naiyer A., et al. "Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer." Science 348.6230 (2015): 124-128.
-
Jung, Steffen, et al. "In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens." Immunity 17.2 (2002): 211-220.
